<VariationArchive VariationID="2138448" VariationName="NM_003560.4(PLA2G6):c.1765_1768del (p.Ser589fs)" VariationType="Deletion" Accession="VCV002138448" Version="2" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-06-23" DateCreated="2023-02-08" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1868603" VariationID="2138448">
      <GeneList>
        <Gene Symbol="PLA2G6" FullName="phospholipase A2 group VI" GeneID="8398" HGNC_ID="HGNC:9039" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>22q13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="38111495" stop="38181830" display_start="38111495" display_stop="38181830" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="38507501" stop="38577835" display_start="38507501" display_stop="38577835" Strand="-" />
          </Location>
          <OMIM>603604</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_003560.4(PLA2G6):c.1765_1768del (p.Ser589fs)</Name>
      <CanonicalSPDI>NC_000022.11:38116185:CAGACAG:CAG</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>22q13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="38116186" stop="38116189" display_start="38116186" display_stop="38116189" variantLength="4" positionVCF="38116185" referenceAlleleVCF="TCAGA" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="38512193" stop="38512196" display_start="38512193" display_stop="38512196" variantLength="4" positionVCF="38512192" referenceAlleleVCF="TCAGA" alternateAlleleVCF="T" />
      </Location>
      <OtherNameList>
        <Name>NM_001004426.3:c.1603_1606del</Name>
      </OtherNameList>
      <ProteinChange>S363fs</ProteinChange>
      <ProteinChange>S411fs</ProteinChange>
      <ProteinChange>S357fs</ProteinChange>
      <ProteinChange>S535fs</ProteinChange>
      <ProteinChange>S589fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.10" sequenceAccession="NC_000022" sequenceVersion="10" change="g.38512196_38512199del" Assembly="GRCh37">
            <Expression>NC_000022.10:g.38512196_38512199del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.11" sequenceAccession="NC_000022" sequenceVersion="11" change="g.38116189_38116192del" Assembly="GRCh38">
            <Expression>NC_000022.11:g.38116189_38116192del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007094.3" sequenceAccession="NG_007094" sequenceVersion="3" change="g.103590_103593del">
            <Expression>NG_007094.3:g.103590_103593del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001004426.3" sequenceAccession="NM_001004426" sequenceVersion="3" change="c.1603_1606del">
            <Expression>NM_001004426.3:c.1603_1606del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001004426.1" sequenceAccession="NP_001004426" sequenceVersion="1" change="p.Ser535fs">
            <Expression>NP_001004426.1:p.Ser535fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001199562.3" sequenceAccession="NM_001199562" sequenceVersion="3" change="c.1603_1606del">
            <Expression>NM_001199562.3:c.1603_1606del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001186491.1" sequenceAccession="NP_001186491" sequenceVersion="1" change="p.Ser535fs">
            <Expression>NP_001186491.1:p.Ser535fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349864.2" sequenceAccession="NM_001349864" sequenceVersion="2" change="c.1765_1768del">
            <Expression>NM_001349864.2:c.1765_1768del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336793.1" sequenceAccession="NP_001336793" sequenceVersion="1" change="p.Ser589fs">
            <Expression>NP_001336793.1:p.Ser589fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349865.2" sequenceAccession="NM_001349865" sequenceVersion="2" change="c.1603_1606del">
            <Expression>NM_001349865.2:c.1603_1606del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336794.1" sequenceAccession="NP_001336794" sequenceVersion="1" change="p.Ser535fs">
            <Expression>NP_001336794.1:p.Ser535fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349866.2" sequenceAccession="NM_001349866" sequenceVersion="2" change="c.1603_1606del">
            <Expression>NM_001349866.2:c.1603_1606del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336795.1" sequenceAccession="NP_001336795" sequenceVersion="1" change="p.Ser535fs">
            <Expression>NP_001336795.1:p.Ser535fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349867.2" sequenceAccession="NM_001349867" sequenceVersion="2" change="c.1231_1234del">
            <Expression>NM_001349867.2:c.1231_1234del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336796.1" sequenceAccession="NP_001336796" sequenceVersion="1" change="p.Ser411fs">
            <Expression>NP_001336796.1:p.Ser411fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349868.2" sequenceAccession="NM_001349868" sequenceVersion="2" change="c.1087_1090del">
            <Expression>NM_001349868.2:c.1087_1090del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336797.1" sequenceAccession="NP_001336797" sequenceVersion="1" change="p.Ser363fs">
            <Expression>NP_001336797.1:p.Ser363fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349869.2" sequenceAccession="NM_001349869" sequenceVersion="2" change="c.1069_1072del">
            <Expression>NM_001349869.2:c.1069_1072del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336798.1" sequenceAccession="NP_001336798" sequenceVersion="1" change="p.Ser357fs">
            <Expression>NP_001336798.1:p.Ser357fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_003560.4" sequenceAccession="NM_003560" sequenceVersion="4" change="c.1765_1768del" MANESelect="true">
            <Expression>NM_003560.4:c.1765_1768del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_003551.2" sequenceAccession="NP_003551" sequenceVersion="2" change="p.Ser589fs">
            <Expression>NP_003551.2:p.Ser589fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1015" sequenceAccession="LRG_1015">
            <Expression>LRG_1015:g.103590_103593del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1015t1" sequenceAccession="LRG_1015t1">
            <Expression>LRG_1015t1:c.1765_1768del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1015p1" sequenceAccession="LRG_1015p1" change="p.Ser589fs">
            <Expression>LRG_1015p1:p.Ser589fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_003560.4(PLA2G6):c.1765_1768del (p.Ser589fs) AND PLA2G6-associated neurodegeneration" Accession="RCV003041415" Version="3">
        <ClassifiedConditionList TraitSetID="33682">
          <ClassifiedCondition DB="MedGen" ID="CN204472">PLA2G6-associated neurodegeneration</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-01-24" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003560.4(PLA2G6):c.1765_1768del (p.Ser589fs) AND Infantile neuroaxonal dystrophy" Accession="RCV003064656" Version="2">
        <ClassifiedConditionList TraitSetID="1718">
          <ClassifiedCondition DB="MedGen" ID="C0270724">Infantile neuroaxonal dystrophy</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-11-05" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-11-05" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2023-02-08" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16783378</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18570303</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18799783</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22213678</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28295203</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1718" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5628" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Infantile neuroaxonal dystrophy 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Seitelberger disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Infantile neuroaxonal dystrophy</ElementValue>
                <XRef ID="Neuroaxonal+dystrophy%2C+infantile/5159" DB="Genetic Alliance" />
                <XRef ID="52713000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0007" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0014" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0015" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0004" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">INAD1</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">NBIA2A</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">INAD</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3957" />
                <XRef ID="3957" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">PLA2G6-Associated Neurodegeneration</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">PLA2G6-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features: Infantile neuroaxonal dystrophy (INAD). Atypical neuroaxonal dystrophy (atypical NAD). PLA2G6-related dystonia-parkinsonism. INAD usually begins between ages six months and three years with psychomotor regression or delay, hypotonia, and progressive spastic tetraparesis. Many affected children never learn to walk or lose the ability shortly after attaining it. Strabismus, nystagmus, and optic atrophy are common. Disease progression is rapid, resulting in severe spasticity, progressive cognitive decline, and visual impairment. Many affected children do not survive beyond their first decade. Atypical NAD shows more phenotypic variability than INAD. In general, onset is in early childhood but can be as late as the end of the second decade. The presenting signs may be gait instability, ataxia, or speech delay and autistic features, which are sometimes the only evidence of disease for a year or more. Strabismus, nystagmus, and optic atrophy are common. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are also common. The course is fairly stable during early childhood and resembles static encephalopathy but is followed by neurologic deterioration between ages seven and 12 years. PLA2G6-related dystonia-parkinsonism has a variable age of onset, but most individuals present in early adulthood with gait disturbance or neuropsychiatric changes. Affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability.</Attribute>
                <XRef ID="NBK1675" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301718</ID>
                <ID Source="BookShelf">NBK1675</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">23447832</ID>
                <ID Source="BookShelf">NBK121988</ID>
              </Citation>
              <XRef ID="35069" DB="Orphanet" />
              <XRef ID="C0270724" DB="MedGen" />
              <XRef ID="MONDO:0024457" DB="MONDO" />
              <XRef Type="MIM" ID="256600" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="33682" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18389" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">phospholipase A2-associated neurodegeneration</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">PLA2G6-associated neurodegeneration</ElementValue>
                <XRef ID="MONDO:0017998" DB="MONDO" />
                <XRef ID="329303" DB="Orphanet" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PLAN</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12567" />
                <XRef ID="12567" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">PLA2G6-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features: Infantile neuroaxonal dystrophy (INAD). Atypical neuroaxonal dystrophy (atypical NAD). PLA2G6-related dystonia-parkinsonism. INAD usually begins between ages six months and three years with psychomotor regression or delay, hypotonia, and progressive spastic tetraparesis. Many affected children never learn to walk or lose the ability shortly after attaining it. Strabismus, nystagmus, and optic atrophy are common. Disease progression is rapid, resulting in severe spasticity, progressive cognitive decline, and visual impairment. Many affected children do not survive beyond their first decade. Atypical NAD shows more phenotypic variability than INAD. In general, onset is in early childhood but can be as late as the end of the second decade. The presenting signs may be gait instability, ataxia, or speech delay and autistic features, which are sometimes the only evidence of disease for a year or more. Strabismus, nystagmus, and optic atrophy are common. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are also common. The course is fairly stable during early childhood and resembles static encephalopathy but is followed by neurologic deterioration between ages seven and 12 years. PLA2G6-related dystonia-parkinsonism has a variable age of onset, but most individuals present in early adulthood with gait disturbance or neuropsychiatric changes. Affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability.</Attribute>
                <XRef ID="NBK1675" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301718</ID>
                <ID Source="BookShelf">NBK1675</ID>
              </Citation>
              <XRef ID="329303" DB="Orphanet" />
              <XRef ID="CN204472" DB="MedGen" />
              <XRef ID="MONDO:0017998" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="6450158" SubmissionDate="2023-01-27" DateLastUpdated="2023-02-07" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="d5d39a25-5a05-4c70-8d2d-d29ac7897628" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV003760980" DateUpdated="2023-02-07" DateCreated="2023-02-07" Type="SCV" Version="1" SubmitterName="Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard" OrgID="506627" OrganizationCategory="laboratory" OrgAbbreviation="Broad RDG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-01-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>The p.Ser589fs variant in PLA2G6 has been reported in 1 individual, in the compound heterozygous state, with PLA2G6-associated neurodegeneration (PMID: 28295203) and has been identified in 0.0009% (1/113476) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs1485023784). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. This variant is predicted to cause a frameshift, which alters the protein‚Äôs amino acid sequence beginning at position 589 and leads to a premature termination codon 76 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the PLA2G6 gene is an established disease mechanism in autosomal recessive PLA2G6-associated neurodegeneration. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic for autosomal recessive PLA2G6-associated neurodegeneration. ACMG/AMP Criteria applied: PVS1, PM2 (Richards 2015).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_001004426.3:c.1603_1606del</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000022.11:g.38116189_38116192del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0017998" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12627697</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="6133247" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="4963799|MedGen:C0270724" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003444346" DateUpdated="2024-02-14" DateCreated="2023-02-07" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-11-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16783378</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18570303</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18799783</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22213678</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28295203</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Ser589Thrfs*76) in the PLA2G6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PLA2G6 are known to be pathogenic (PMID: 16783378, 18570303, 18799783, 22213678). This variant is present in population databases (no rsID available, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with infantile neuroaxonal dystrophy (PMID: 28295203). ClinVar contains an entry for this variant (Variation ID: 2138448). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000022.10:g.38512193_38512196del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0270724" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="6450158" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0017998" MappingRef="MONDO">
        <MedGen CUI="CN204472" Name="PLA2G6-associated neurodegeneration" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="6133247" TraitType="Disease" MappingType="XRef" MappingValue="C0270724" MappingRef="MedGen">
        <MedGen CUI="C0270724" Name="Infantile neuroaxonal dystrophy" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

